Author Archives: Julian Upton

Europe: EFPIA Campaign Calls for Integrated Life Sciences Strategy

The European Federation of Pharmaceutical Industries and Associations (EFPIA) has launched a social media campaign calling for an integrated life sciences  strategy for the EU. The #HealthyEU Health and Growth campaign will outline the opportunities and threats faced by patients and the healthcare sector today, and provide evidence and facts to inform healthcare debates in the run […]
Posted in E-Media, Europe, Events, Global, multimedia, Regulatory, social media, Strategy | Tagged , , , , , | Leave a comment

Bioscience Research: China to Overtake U.S. by 2020

Bioscience research in China is set to overtake the United States within the next five to ten years, according to data from search engine CiteAb.
Posted in Biotech, Emerging Markets, Gene therapy, Global, R&D | Tagged , , , , | Leave a comment

Pharma Seizes Latin American Opportunities

Approximately $12.7 billion has been invested in Latin America’s (LATAM’s) pharmaceutical market through mergers and acquisitions (M&As) in recent years. And with untapped potential identified in countries across the region, companies are expected to seize upon further opportunities to drive future growth, says a new report from GlobalData.
Posted in Emerging Markets, Market Access | Tagged , , , , , , | Leave a comment

Crohn's Disease Market to Show Modest Growth to 2022

The global Crohn’s disease (CD) market value is forecast to show modest growth, climbing from $3.2 billion in 2012 to $4.2 billion by 2022, at a Compound Annual Growth Rate (CAGR) of 2.8%, according to a new report from research and consulting firm GlobalData. The company’s latest report states that out of the 10 major […]
Posted in Global, Strategy | Tagged , , | Leave a comment

NICE's Tarceva Decision "Perverse", Says Roche

The UK National Institute for Health and Care Excellence’s (NICE) decision that relapsed non-small cell lung cancer patients should no longer have access to Roche’s cancer pill Tarceva (erlotinib) is a setback for lung cancer care in England and Wales, where “over 1,000 patients a year will be left without an active treatment option after […]
Posted in pricing, Regulatory | Tagged , , , , , | Leave a comment
  • Categories

  • Meta